Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.

cold agglutinin
therapeutic agents
measurable disease
fever
monoclonal protein
  • 0 views
  • 14 Mar, 2022
  • 5 locations
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01)

This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate

measurable disease
lenalidomide
b-cell lymphoma
ibrutinib
gilbert's syndrome
  • 2 views
  • 28 Apr, 2022
  • 12 locations
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.

  • 10 views
  • 26 Apr, 2022
  • 7 locations
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.

potassium
measurable disease
cancer
diffuse large b-cell lymphoma
b-cell lymphoma
  • 26 views
  • 14 May, 2022
  • 7 locations
Front Line Ibrutinib for Newly Diagnosed Chronic Graft-Versus Host Disease

see if ibrutinib as a first-line treatment can help people with newly diagnosed cGVHD. Eligibility People age 18 and older with newly diagnosed moderate or severe

immunosuppression
beclomethasone
bone marrow transplant
immunosuppressive agents
ibrutinib
  • 0 views
  • 15 May, 2022
  • 2 locations
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective

cancer
transformed lymphoma
b-cell lymphoma
mantle cell lymphoma
bone marrow procedure
  • 97 views
  • 11 May, 2022
  • 1 location
Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease

cGVHD are steroids, however, up to 50% of patients do not respond to treatment. There is no well-defined second-line treatment for cGVHD, but ibrutinib, a Bruton tyrosine kinase inhibitor, has been

  • 0 views
  • 09 May, 2022
  • 1 location
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous

  • 3 views
  • 04 Feb, 2022
  • 7 locations
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients

lymphoid leukemia
chronic lymphocytic leukemia
fludarabine
lymphadenopathy
anemia
  • 5 views
  • 09 Feb, 2022
  • 1 location
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

and the efficacy of the combination of cluster of anti differentiation antigen 20 (anti-CD20) antibody (e.g. Obinutuzumab or Rituximab) with Ibrutinib and/or Venetoclax have been already reported in

  • 0 views
  • 15 Dec, 2021
  • 4 locations